Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia
Part of paid clinical trials in Duarte, California.
- Sponsor
- National Cancer Institute (NCI)
- Study ID
- NCT06311227
- Phase
- PHASE2
- Status
- Active Not Recruiting
Conditions
- Recurrent Hairy Cell Leukemia
- Recurrent Hairy Cell Leukemia Variant
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Biospecimen Collection — PROCEDUREUndergo blood sample collection
- Bone Marrow Aspiration — PROCEDUREUndergo bone marrow aspiration
- Bone Marrow Biopsy — PROCEDUREUndergo bone marrow biopsy
- Computed Tomography — PROCEDUREUndergo CT scan
- Lumbar Puncture — PROCEDUREUndergo lumbar puncture
- Magnetic Resonance Imaging — PROCEDUREUndergo MRI
- Venetoclax — DRUGGiven PO
Study Details
This phase II trial tests how well venetoclax works in treating patients with hairy cell leukemia that has come back after a period of improvement (relapsed). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival.
Key Dates
- First listed
- Mar 15, 2024
- Start date
- Dec 16, 2024
- Status verified
- Sep 2026
- Primary completion
- May 20, 2027
- Completion
- May 20, 2027
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Treatment (venetoclax)Patients receive venetoclax PO QD on days 1-28 of each cycle. Treatment repeats every 28 days for up to 19 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT or MRI and blood sample collection throughout the study. Patients may undergo bone marrow biopsy and/or aspiration on study. Additionally, patients with known or suspected CNS disease undergo lumbar puncture throughout the study.
Primary Outcome Measure
Objective response rate [ Time Frame: Up to 30 days after the last dose ]
Locations (21)
Find similar trials in Duarte, CA
By research site
City of Hope Comprehensive Cancer Center· Duarte, CACity of Hope at Irvine Lennar· Irvine, CAUM Sylvester Comprehensive Cancer Center at Aventura· Aventura, FLUM Sylvester Comprehensive Cancer Center at Coral Gables· Coral Gables, FLUM Sylvester Comprehensive Cancer Center at Coral Springs· Coral Springs, FLUM Sylvester Comprehensive Cancer Center at Deerfield Beach· Deerfield Beach, FL
Related Studies
- Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell LeukemiaPHASE1/PHASE2 · Recruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Cladribine and Rituximab in Treating Patients With Hairy Cell LeukemiaPHASE2 · Recruiting · M.D. Anderson Cancer Center · Houston, Texas